Page 381 - Read Online

Mura et al. The peritoneal metastases from GC

very aggressive disease with very poor prognosis. In peritoneal metastases. World J Gastrointest Oncol 2016;8:67-82.
selected GC patients with low peritoneal tumor burden, 8. Strieter RM. Chemokines: not just leukocyte chemoattractants in the
more aggressive multi-modal strategy with CRS plus 9. promotion of cancer. Nat Immunol 2001;2:285-6.
Geminder H, Sagi-Assif O, Goldberg L, Meshel T, Rechavi G, Witz
intraperitoneal treatment as HIPEC may achieve long- IP, Ben-Baruch A. A possible role for CXCR4 and its ligand, the CXC
term survival results with up to 25% 5-year survival chemokine stromal cell-derived factor-1, in the development of bone
rates in case of complete cytoreduction. Moreover, marrow metastases in neuroblastoma. J Immunol 2001;167:4747-57.
there are strong evidences for HIPEC in adjuvant 10. Jones D, Benjamin RJ, Shahsafaei A, Dorfman DM. The chemokine
setting after radical surgery for preventing PC in high receptor CXCR3 is expressed in a subset of B-cell lymphomas
risk GC patients. Intraperitoneal immunotherapy, and is a marker of B-cell chronic lymphocytic leukemia. Blood
2000;95:627-32.
when associated with radical surgery, may open very 11. Rempel SA, Dudas S, Ge S, Gutiérrez JA. Identification and
interesting perspectives for the future. The detection localization of the cytokine SDF1 and its receptor, CXC chemokine
of free peritoneal cancer cells is the more realistic receptor 4, to regions of necrosis and angiogenesis in human
and practical way for the identification of patients at glioblastoma. Clin Cancer Res 2000;6:102-11.
risk of carcinomatosis after surgery. The routine use 12. Yasumoto K, Koizumi K, Kawashima A, Saitoh Y, Arita Y, Shinohara
of techniques of molecular detection in peritoneal K, Minami T, Nakayama T, Sakurai H, Takahashi Y, Yoshie O, Saiki
washing appears to be the more sensitive method. I. Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of
gastric cancer. Cancer Res 2006;66:2181-7.
Such patients are potential candidate for multimodal 13. Lee HJ, Jo DY. The role of the CXCR4/CXCL12 axis and its clinical
and locoregional treatments in order to prevent the implications in gastric cancer. Histol Histopathol 2012;27:1155-61.
peritoneal recurrence. 14. Bachelder RE, Wendt MA, Mercurio AM. Vascular endothelial
growth factor promotes breast carcinoma invasion in an autocrine
Financial support and sponsorship manner by regulating the chemokine receptor CXCR4. Cancer Res
Nil. 2002;62:7203-6.
15. Sugarbaker PH, Yu W, Yonemura Y. Gastrectomy, peritonectomy,
Conflicts of interest and perioperative intraperitoneal chemotherapy: the evaluation of
There are no conflicts of interest. treatment strategies for advanced gastric cancer. Semin Surg Oncol
2003;21:233-48.
Patient consent 16. Mebius RE. Lymphoid organs for peritoneal cavity immune response:
milky spots. Immunity 2009;30:670-2.
Obtained. 17. Miao ZF, Wang ZN, Zhao TT, Xu YY, Gao J, Miao F, Xu HM.
Peritoneal milky spots serve as a hypoxic niche and favor gastric
Ethics approval cancer stem/progenitor cell peritoneal dissemination through hypoxia-
The patient was treated within the standards of inducible factor 1α. Stem Cells 2014;32:3062-74.
authors’ institute and the report was approved. 18. Yonemura Y, Endo Y, Yamaguchi T, Fujimura T, Obata T, Kawamura
T, Nojima N, Miyazaki I, Sasaki T. Mechanisms of the formation of the
peritoneal dissemination in gastric cancer. Int J Oncol 1996;8:795-802.
REFERENCES 19. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ.
Multivariate prognostic factor analysis in locally advanced and
1. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, metastatic esophago-gastric cancer -- pooled analysis from three
Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL, multicenter, randomized, controlled trials using individual patient
François Y, Vignal J, Gilly FN. Peritoneal carcinomatosis from non- data. J Clin Oncol 2004;22:2395-403.
gynecologic malignancies: results of the EVOCAPE 1 multicentric 20. Kim JG, Ryoo BY, Park YH, Kim BS, Kim TY, Im YH, Kang YK.
prospective study. Cancer 2000;88:358-63. Prognostic factors for survival of patients with advanced gastric
2. Sugarbaker PH, Yonemura Y. Clinical pathway for the management of cancer treated with cisplatin-based chemotherapy. Cancer Chemother
resectable gastric cancer with peritoneal seeding: best palliation with Pharmacol 2008;61:301-7.
a ray of hope for cure. Oncology 2000;58:96-107. 21. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M,
3. Thomassen I, van Gestel YR, van Ramshorst B, Luyer MD, Bosscha K, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H,
Nienhuijs SW, Lemmens VE, de Hingh IH. Peritoneal carcinomatosis Higashino M, Yamamura Y, Kurita A, Arai K; ACTS-GC Group.
of gastric origin: a population-based study on incidence, survival and Adjuvant chemotherapy for gastric cancer with S-1, an oral
risk factors. Int J Cancer 2014;134:622-8. fluoropyrimidine. N Engl J Med 2007;357:1810-20.
4. Yonemura Y, Bandou E, Kinoshita K, Kawamura T, Takahashi S, 22. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee
Endou Y, Sasaki T. Effective therapy for peritoneal dissemination in KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS,
gastric cancer. Surg Oncol Clin N Am 200312:635-48. Button P, Sirzén F, Noh SH; CLASSIC trial investigators. Adjuvant
5. Neuwirth MG, Alexander HR, Karakousis GC. Then and now: capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy
cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet
(HIPEC), a historical perspective. J Gastrointest Oncol 2016;7:18-28. 2012;379:315-21.
6. Yonemura Y, Bando E, Kawamura T, Ito H, Endo Y, Miura M, Kiyosaki 23. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de
K, Sasaki T. Cytoreduction and intraperitoneal chemotherapy for Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ,
carcinomatosis from gastric cancer. Cancer Treat Res 2007;134:357-73. Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial
7. Lungoci C, Mironiuc AI, Muntean V, Oniu T, Leebmann H, Mayr M, Participants. Perioperative chemotherapy versus surgery alone for
Piso P. Multimodality treatment strategies have changed prognosis of resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20.
Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ September 18, 2016 371